Login to Your Account

CNS drug developer Promentis lands $26M series C

By Michael Fitzhugh
Staff Writer

Wednesday, March 29, 2017

Promentis Pharmaceuticals Inc., a Milwaukee-based company developing therapies for CNS, has completed a $26 million series C financing to help it advance its lead compound, SXC-2023, through phase II proof of concept.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription